Physician profile
Robert White
NPI 1396718938
$7,628.51
in general payments reported to CMS, 2019-2025
63 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,720 · 2020: $1,090 · 2021: $2,252 · 2022: $486 · 2023: $353 · 2024: $355 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $967.64 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $657.64 | 2019-2021 | |
| Emd Serono, INC. | $614.72 | 2019-2020 | |
| Ucb, INC. | $373.47 | 2019-2025 | Briviact |
| Biogen, INC. | $335.34 | 2019-2025 | Tysabri |
| Genzyme Corporation | $332.24 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $266.73 | 2019-2021 | |
| Genentech USA, INC. | $251.22 | 2019-2024 | Ocrevus |
| Abbvie INC. | $235.98 | 2019-2025 | Duopa |
| Grifols USA, LLC | $209.42 | 2019-2025 | Gamunex-C |
| Sk Life Science, INC. | $190.90 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $185.50 | 2019-2021 | |
| Csl Behring | $178.16 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $154.23 | 2019-2024 | Ongentys 50mg Capsules 30, Rytary |
| Allergan, INC. | $146.50 | 2019-2021 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.